Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities

Patient

Volumn 7, Issue 4, 2014, Pages 437-450

  Brod, Meryl ^a   Alolga, Suzanne Lessard ^a   Meneghini, Luigi ^b  

^a Brod Group   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; BLOOD GLUCOSE MONITORING; CLINICAL DECISION MAKING; DIABETIC PATIENT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH BELIEF; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICATION THERAPY MANAGEMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT EDUCATION; WEIGHT GAIN; DECISION MAKING; DIABETES MELLITUS, TYPE 2; EUROPE; INFORMATION PROCESSING; MIDDLE AGED; PATIENT PARTICIPATION; PSYCHOLOGY; RISK FACTOR; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DECISION MAKING; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; RISK FACTORS; UNITED STATES;

EID: 84911984812     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-014-0068-x     Document Type: Article

References (66)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.
2. World Health Organization. Diabetes. Fact Sheet. Number 31 World Health Organization. 2012 http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 29 Nov 2012.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.” BMJ. 2000;321:405–12.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
5. Logtenberg SJ, Kleefstra N, Ubink-Veltmaat LJ, Houweling ST, Bilo HJ. Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5). Fam Pract. 2007;24:529–31.
6. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia. 1999;42:926–31.
7. Wild SH, Smith FB, Lee AJ, Fowkes FG. Criteria for previously undiagnosed diabetes and risk of mortality: 15-year follow-up of the Edinburgh Artery Study cohort. Diabet Med. 2005;22:490–6.
8. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J. 2007;100:164–74.
9. Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: Effective, safe, and well accepted. J Investig Med. 2007;55:62–8.
10. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type 2 diabetes: a progressive disease. UK Prospective Diabetes Study Group [erratum in Diabetes. 1996;45:1655]. Diabetes. 1995;44:1249–58.
11. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.
12. Brod M, Kongsø JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18:23–32.
13. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34:511–7.
14. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543–5.
15. Wang HF, Yeh MC. Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review. J Adv Nurs. 2012;68:743–57.
16. Woudenberg YJ, Lucas C, Latour C, Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012;29:796–802.
17. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9.
18. Nathan DM. Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342–9.
19. Davis SN, Renda SM. Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ. 2006;32:146S–52S.
20. Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes and Needs (DAWN) Japan study. PLoS One. 2012;7:e36361.
21. Ratanawongsa N, Crosson JC, Schillinger D, Karter AJ, Saha CK, Marrero DG. Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. Diabetes Educ. 2012;38:94–100.
22. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161:1653–9.
23. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18(Suppl 3):S42–9.
24. Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, et al. Barriers to insulin initiation: the Translating Research Into Action for Diabetes Insulin Starts Project. Diabetes Care. 2010;33:733–5.
25. Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25:36–8.
26. Lawton J, Peel E, Parry O, Douglas M. Patients’ perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. Diabet Med. 2008;25:491–5.
27. Hinder S, Greenhalgh T. “This does my head in”. Ethnographic study of self-management by people with diabetes. BMC Health Serv Res. 2012. doi:10.1186/1472-6963-12-83.
28. Gucciardi E, Fortugno M, Senchuk A, Beanlands H, McCay E, Peel EE. Self-monitoring of blood glucose in Black Caribbean and South Asian Canadians with non-insulin treated type 2 diabetes mellitus: a qualitative study of patients’ perspectives. BMC Endocr Disord. 2013. doi:10.1186/1472-6823-13-46.
29. Hortensius J, Kars MC, Wierenga WS, Kleefstra N, Bilo HJ, van der Bijl JJ. Perspectives of patients with type 1 or insulin-treated type 2 diabetes on self-monitoring of blood glucose: a qualitative study. BMC Public Health. 2012. doi:10.1186/1471-2458-12-167.
30. Peel E, Parry O, Douglas M, Lawton J. Blood glucose self-monitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients’ perspectives. Br J Gen Pract. 2004;54:183–8.
31. Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients’ perspectives. BMJ. 2007;335:493.
32. Beverly E, Ritholz M, Brooks K, Hultgren B, Lee Y, Abrahamson M, et al. A qualitative study of perceived responsibility and self-blame in type 2 diabetes: reflections of physicians and patients. J Gen Intern Med. 2012;27:1180–7.
33. Carbone ET, Rosal MC, Torres MI, Goins KV, Bermudez OI. Diabetes self-management: perspectives of Latino patients and their health care providers. Patient Educ Couns. 2007;66:202–10.
34. Nagelkerk J, Reick K, Meengs L. Perceived barriers and effective strategies to diabetes self-management. J Adv Nurs. 2006;54:151–8.
35. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q. 1988;15:175–83.
36. Harvey JN, Lawson VL. The importance of health belief models in determining self-care behaviour in diabetes. Diabet Med. 2009;26:5–13.
37. Champion V, Skinner CS. The Health Belief Model. In: Glanz K, Rimer BK, Viswanath K, editors. Health behavior and health education: theory, research, and practice. San Francisco: Jossey-Bass; 2008. p. 45–65.
38. Hayden JA. Introduction to health behavior theory. 2nd ed. Burlington: Jones & Bartlett Learning; 2014.
39. Brod M, Tesler LE, Christensen T. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18:1263–78.
40. Saldana J. The coding manual for qualitative researchers. Los Angeles: Sage; 2010.
41. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007;10:S94–105.
42. National Diabetes Information Clearinghouse (NDIC). http://diabetes.niddk.nih.gov. Accessed 6 Dec 2010.
43. American Diabetes Association. http://www.diabetes.org. Accessed 6 Dec 2010.
44. American Diabetes Association. Insulin myths and facts. http://clinical.diabetesjournals.org/content/25/1/39.full. Accessed 4 Oct 2010.
45. Mayo Clinic.com. http://www.mayoclinic.com/health/diabetes/DS01121. Accessed 6 Dec 2010.
46. Joslin Diabetes Center. http://www.joslin.org/diabetes-information.html. Accessed 4 Oct 2010.
47. UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
48. Joslin Diabetes Center. Joslin Injection Training Tools: addressing patient concerns. http://www.bd.com/us/diabetes/hcp/main.aspx?cat=3065&id=63266. Accessed 14 Mar 2013.
49. American Association of Diabetes Educators (AADE). Strategies for insulin injection therapy in diabetes self-management. http://www.diabeteseducator.org/export/sites/aade/_resources/pdf/research/AADE_MedEd.pdf. Accessed 14 Mar 2013.
50. Johns Hopkins Medicine. Insulin therapy: friend, not foe. It’s time to dispel common myths about insulin treatment for people with type 2 diabetes. Johns Hopkins Med Lett Health After. 2011;23:4–5.
51. Minze MG, Dalal K, Irons BK. Removing barriers to insulin use. J Fam Pract. 2011;60:577–80.
52. Peyrot M, Rubin RR, Khunit K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4:S11–8.
53. Novo Nordisk. Changing my diabetes—insulin dialogue toolkit. http://www.dawnstudy.com/News_and_activities/insulin_dialogue_toolkit.asp. Accessed 14 Mar 2013.
54. Alberti G. The DAWN (Diabetes Attitudes, Wishes and Needs) study. Pract Diab Int. 2002;19:22–4a.
55. Skovlund SE, Peyrot M. The Diabetes Attitudes, Wishes, and Needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum. 2005;18:136–42.
56. Skovlund SE. Diabetes attitudes, wishes and needs. Diabetes Voice. 2004;49:4–11.
57. Hermanns N, Mahr M, Kulzer B, Skovlund SE, Haak T. Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study. Health Qual Life Outcomes. 2010;8:113.
58. Ruiz MA, Pardo A, Martinez de la Casa JM, Polo V, Esquiro J, Soto J. Development of a specific questionnaire measuring patient satisfaction with glaucoma treatment: Glausat. Ophthalmic Epidemiol. 2010;17:131–43.
59. Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49:448–56.
60. Biderman A, Noff E, Harris SB, Friedman N, Levy A. Treatment satisfaction of diabetic patients: what are the contributing factors? Fam Pract. 2009;26:102–8.
61. Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007;30:1399–405.
62. Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes. 2007;5:8.
63. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res. 2006;15:481–91.
64. Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65:408–14.
65. Martinez L, Consoli SM, Monnier L, Simon D, Wong O, Yomtov B, et al. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. Health Qual Life Outcomes. 2007;5:53.
66. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the Insulin Treatment Appraisal Scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;20(5):69.